NCT05693844View on ClinicalTrials.gov

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced or Metastatic Solid Tumors
Interventions
BIOLOGICAL

Pan-T booster co-expressing MSLN CAR T cell

Starting Dose: 1×10\^6 cells/kg

DRUG

Albumin-bound paclitaxel

Administered intravenously at dose of 100-200mg/m2 on day -5

DRUG

Cyclophosphamide

Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2

DRUG

Fludarabine

Administered intravenously at dose of 30mg/m2/d on day -3 and day -2

Trial Locations (1)

100853

RECRUITING

Kaichao Feng, Beijing

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Chinese PLA General Hospital

OTHER